Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1974 1
1975 5
1976 6
1977 1
1978 1
1979 2
1980 3
1981 5
1982 7
1983 7
1984 9
1985 16
1986 10
1987 18
1988 20
1989 18
1990 18
1991 28
1992 22
1993 34
1994 37
1995 22
1996 31
1997 19
1998 30
1999 37
2000 28
2001 53
2002 75
2003 91
2004 82
2005 60
2006 73
2007 49
2008 57
2009 65
2010 78
2011 87
2012 79
2013 79
2014 99
2015 127
2016 125
2017 122
2018 125
2019 119
2020 103
2021 106
2022 108
2023 98
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

2,246 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Chronic Leukemia"
Page 1
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.
Hallek M, Al-Sawaf O. Hallek M, et al. Am J Hematol. 2021 Dec 1;96(12):1679-1705. doi: 10.1002/ajh.26367. Am J Hematol. 2021. PMID: 34625994 Free article. Review.
DISEASE OVERVIEW: Chronic lymphocytic leukemia (CLL) is one of the most frequent types of leukemia. ...Alternative therapies are needed for patients with BTK and BCL2 inhibitor double-refractory disease....
DISEASE OVERVIEW: Chronic lymphocytic leukemia (CLL) is one of the most frequent types of leukemia. ...Alternative ther …
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.
Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KH, Kanagal-Shamanna R, Khoury JD, Patel K, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Haddad FG, Kwari M, Thankachan J, Delumpa R, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Jabbour E, et al. Lancet Haematol. 2023 Jan;10(1):e24-e34. doi: 10.1016/S2352-3026(22)00319-2. Epub 2022 Nov 16. Lancet Haematol. 2023. PMID: 36402146 Clinical Trial.
METHODS: We did a single-centre, single-arm, phase 2 study at the University of Texas MD Anderson Cancer Center, Houston, TX, USA, in patients aged 18 years or older with newly diagnosed or relapsed or refractory Ph-positive acute lymphoblastic leukaemia or chron …
METHODS: We did a single-centre, single-arm, phase 2 study at the University of Texas MD Anderson Cancer Center, Houston, TX, USA, in patien …
ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Hillmen P, Brown JR, Eichhorst BF, Lamanna N, O'Brien SM, Qiu L, Salmi T, Hilger J, Wu K, Cohen A, Huang J, Tam CS. Hillmen P, et al. Future Oncol. 2020 Apr;16(10):517-523. doi: 10.2217/fon-2019-0844. Epub 2020 Mar 24. Future Oncol. 2020. PMID: 32207333 Free article.
Treatment standards for chronic lymphocytic leukemia (CLL) have been transformed with the advent of effective inhibitors of B-cell receptor signaling such as ibrutinib - a first-in-class inhibitor of BTK. ...Described here is a head-to-head Phase III study comparing …
Treatment standards for chronic lymphocytic leukemia (CLL) have been transformed with the advent of effective inhibitors of B- …
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.
Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, Riedell PA, Shah NN, Nath R, Fakhri B, Stephens DM, Ma S, Feldman T, Solomon SR, Schuster SJ, Perna SK, Tuazon SA, Ou SS, Papp E, Peiser L, Chen Y, Wierda WG. Siddiqi T, et al. Lancet. 2023 Aug 19;402(10402):641-654. doi: 10.1016/S0140-6736(23)01052-8. Epub 2023 Jun 6. Lancet. 2023. PMID: 37295445 Clinical Trial.
BACKGROUND: Patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma for whom treatment has failed with both Bruton tyrosine kinase (BTK) inhibitor and venetoclax have few treatment options and poor outcomes. We aimed t …
BACKGROUND: Patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma for whom t …
Ofatumumab.
Sanford M, McCormack PL. Sanford M, et al. Drugs. 2010 May 28;70(8):1013-9. doi: 10.2165/11203850-000000000-00000. Drugs. 2010. PMID: 20481657 Review.
In a pivotal, noncomparative study in patients with fludarabine- and alemtuzumab-refractory chronic lymphocytic leukaemia (CLL), ofatumumab induced objective responses in 58% (99% CI 40, 74) of patients, which met a prespecified superiority criterion. ...The …
In a pivotal, noncomparative study in patients with fludarabine- and alemtuzumab-refractory chronic lymphocytic leukaemia …
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.
Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, Kadia T, Takahashi K, Masarova L, Short N, Alvarado Y, Yilmaz M, Ravandi F, Andreeff M, Kanagal-Shamanna R, Ganan-Gomez I, Colla S, Qiao W, Huang X, McCue D, Mirabella B, Kantarjian H, Garcia-Manero G. Bazinet A, et al. Lancet Haematol. 2022 Oct;9(10):e756-e765. doi: 10.1016/S2352-3026(22)00216-2. Epub 2022 Sep 2. Lancet Haematol. 2022. PMID: 36063832 Clinical Trial.
We therefore aimed to evaluate the safety, tolerability, and preliminary activity of azacitidine combined with venetoclax for treatment-naive and relapsed or refractory high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia. ...We enrolled pa …
We therefore aimed to evaluate the safety, tolerability, and preliminary activity of azacitidine combined with venetoclax for treatment-naiv …
Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia.
Ottaviano G, Georgiadis C, Gkazi SA, Syed F, Zhan H, Etuk A, Preece R, Chu J, Kubat A, Adams S, Veys P, Vora A, Rao K, Qasim W; TT52 CRISPR-CAR group. Ottaviano G, et al. Sci Transl Med. 2022 Oct 26;14(668):eabq3010. doi: 10.1126/scitranslmed.abq3010. Epub 2022 Oct 26. Sci Transl Med. 2022. PMID: 36288281 Clinical Trial.
Three cell banks of TT52CAR19 T cells were generated and cryopreserved. A phase 1, open-label, non-randomized clinical trial was conducted and treated six children with relapsed/refractory CD19-positive B cell acute lymphoblastic leukemia (B-ALL …
Three cell banks of TT52CAR19 T cells were generated and cryopreserved. A phase 1, open-label, non-randomized clinical tria …
Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past.
Short NJ, Kantarjian H. Short NJ, et al. Lancet Haematol. 2023 May;10(5):e382-e388. doi: 10.1016/S2352-3026(23)00064-9. Epub 2023 Mar 29. Lancet Haematol. 2023. PMID: 37003279 Review.
In this Viewpoint, we review promising data from ongoing clinical trials of novel immunotherapy-based combinations that are being explored in patients with newly diagnosed acute lymphocytic leukaemia. We also discuss the challenges of randomised studies in th …
In this Viewpoint, we review promising data from ongoing clinical trials of novel immunotherapy-based combinations that are being exp …
Current Treatment Options in Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: a Review.
Islam P. Islam P. Curr Treat Options Oncol. 2023 Sep;24(9):1259-1273. doi: 10.1007/s11864-023-01112-0. Epub 2023 Jul 6. Curr Treat Options Oncol. 2023. PMID: 37407887 Review.
Treatment of relapsed and refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) has changed dramatically over the past decade due to the development of oral targeted agents in several therapeutic classes, including BTK inhibitors (suc …
Treatment of relapsed and refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) has changed dr …
Decitabine/Cedazuridine: First Approval.
Dhillon S. Dhillon S. Drugs. 2020 Sep;80(13):1373-1378. doi: 10.1007/s40265-020-01389-7. Drugs. 2020. PMID: 32860582 Free PMC article. Review.
A fixed dose oral combination (FDC) of decitabine and cedazuridine (Inqovi()), is being developed by Astex Pharmaceuticals (a subsidiary of Otsuka Pharmaceuticals) for the treatment of various cancers like myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemi …
A fixed dose oral combination (FDC) of decitabine and cedazuridine (Inqovi()), is being developed by Astex Pharmaceuticals (a subsidiary of …
2,246 results